ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)

HKG:1541 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	647.73	679.56	477.6	306.98	635.21	668.33
Short-Term Investments	-	40	-	42.5	-	-
Trading Asset Securities	298.89	296.46	274.52	259.09	-	-
Cash & Short-Term Investments	946.62	1,016	752.12	608.56	635.21	668.33
Cash Growth	34.52%	35.09%	23.59%	-4.20%	-4.96%	-
Accounts Receivable	0.18	0	0.02	0.04	0.07	0.03
Other Receivables	-	14.15	0.17	1.04	0.96	0.02
Receivables	0.18	14.15	0.18	1.08	1.02	0.06
Inventory	-	25.56	24.54	76.77	9.04	19.42
Other Current Assets	44.77	0.97	91.09	0.29	6.59	16.3
Total Current Assets	991.56	1,057	867.94	686.7	651.87	704.1
Property, Plant & Equipment	27.2	33.53	47.71	149.39	163.89	154.12
Other Long-Term Assets	11.55	8.17	6.35	38.5	24.22	34.62
Total Assets	1,030	1,098	922	874.59	839.98	892.84

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	53.85	13.68	43.24	10.8	1.26	1.76
Accrued Expenses	-	37.03	28.59	30.86	28.91	24.17
Short-Term Debt	-	-	-	59.98	-	-
Current Portion of Long-Term Debt	313.07	188.47	100.89	-	-	-
Current Portion of Leases	5.54	6.86	6.42	4.4	5.6	5.1
Current Income Taxes Payable	-	1.3	1.11	0.77	0.61	2.96
Current Unearned Revenue	-	25.25	32.9	-	-	-
Other Current Liabilities	-	2.98	1.49	9.11	15.36	2,444
Total Current Liabilities	372.46	275.57	214.64	115.91	51.74	2,478
Long-Term Debt	29.4	25.5	14.5	-	-	-
Long-Term Leases	5.13	7.2	14.55	10.4	9.02	13.44
Total Liabilities	406.99	308.27	243.69	126.3	60.76	2,491

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	431.51	431.51	407.31	374.16	356.09	6.91
Additional Paid-In Capital	-	1,384	1,093	913.46	654.47	-
Retained Earnings	-	-1,245	-1,026	-710.35	-330.89	-1,638
Comprehensive Income & Other	194.43	221.06	205.21	171.01	99.54	32.24
Total Common Equity	625.94	791.44	678.9	748.29	779.22	-1,598
Minority Interest	-2.61	-1.3	-0.6	-	-	-
Shareholders' Equity	623.33	790.13	678.31	748.29	779.22	-1,598
Total Liabilities & Equity	1,030	1,098	922	874.59	839.98	892.84

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	353.14	228.03	136.36	74.77	14.62	18.54
Net Cash (Debt)	593.48	788	615.76	533.79	620.59	649.79
Net Cash Growth	7.91%	27.97%	15.36%	-13.99%	-4.49%	-
Net Cash Per Share	1.41	1.91	1.63	1.48	1.87	7.54
Filing Date Shares Outstanding	432.07	431.51	407.31	374.16	356.09	86.18
Total Common Shares Outstanding	432.07	431.51	407.31	374.16	356.09	86.18
Working Capital	619.11	781.14	653.3	570.79	600.13	-1,774
Book Value Per Share	1.45	1.83	1.67	2.00	2.19	-18.55
Tangible Book Value	625.94	791.44	678.9	748.29	779.22	-1,598
Tangible Book Value Per Share	1.45	1.83	1.67	2.00	2.19	-18.55
Machinery	-	53.82	52.89	51.44	49.93	40.87
Construction In Progress	-	-	27.4	22.69	22.46	3.22
Leasehold Improvements	-	22.49	22.49	22.49	22.49	21.07

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 27, 2026

Data Sources Report a data error